To the Editor.
—We read with interest the editorial by Feigenbaum and Pepose1 on screening corneal donors for transmissible disease. The authors discuss the dilemma posed to the eye-banking community: the growing number of serologic tests employed in organ and tissue donation and their applicability to corneal transplantation. Specifically, Feigenbaum and Pepose call into question the process by which new tests are mandated by the Medical Standards Committee of the Eye Bank Association of America (EBAA). We certainly agree with their stated concerns that the choice of serologic testing be based on a number of factors, including the underlying infection rate in the donor population, the sensitivity of the screening test employed, the transmissibility of the agent through corneal transplantation, an assessment of the cost of transmitting the organism from donor to recipient, and a careful cost-benefit analysis based on both the direct costs incurred as well as the
Mannis MJ, Sugar J. Screening Donor Tissue: A Safe and Rational Approach. Arch Ophthalmol. 1992;110(6):751. doi:10.1001/archopht.1992.01080180021007